Literature DB >> 22149259

Enhanced integrin mediated signaling and cell cycle progression on fibronectin mimetic peptide amphiphile monolayers.

Kamlesh Shroff1, Timothy R Pearce, Efrosini Kokkoli.   

Abstract

In recent years, a variety of biomimetic constructs have emerged which mimic the bioactive sequences found in the natural extracellular matrix (ECM) proteins such as fibronectin (FN) that promote cell adhesion as well as proliferation on artificially functionalized interfaces. Much interest lies in investigating the ability of the ECM mimetic materials in regulating a number of vital cell functions including differentiation, gene expression, migration, and proliferation. A peptide amphiphile PR_b containing both the cell adhesive GRGDSP and synergistic PHSRN peptide sequences was developed in our group that was shown to support enhanced cell proliferation and ECM FN secretion as compared to GRGDSP and FN functionalized interfaces. In this study, we have investigated the binding affinity of the PR_b peptide ligand with the FN cell surface receptor, the α(5)β(1) integrin. We compared PR_b functionalized surfaces with FN and BSA coated surfaces and GRGDSP functionalized surfaces in terms of promoting intracellular signaling cascades that are essential for enhanced cellular activity. Specifically, we studied the phosphorylation of focal adhesion kinase (FAK) at tyrosine residues Y397 and Y576 and the formation of cyclin D1, both of which are intracellular markers of integrin mediated attachment of cells, signaling pathways, and progression of cell cycle. FAK and cyclin D1 encourage enhanced cell proliferation, differentiation, and gene expression. Our results show that the PR_b peptide ligand has a specific and strong binding affinity for the α(5)β(1) integrin with a dissociation constant of 76.3 ± 6.3 nM. The PR_b peptide ligands supported enhanced FAK phosphorylation activity and increased cyclin D1 formation as compared to the widely used GRGDSP ligand, the native protein FN (positive control), and BSA nonadhesive surfaces (negative control). These results encourage the use of the FN mimetic PR_b peptide in functionalizing biomaterials for potential tissue engineering and therapeutic applications.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22149259     DOI: 10.1021/la203322t

Source DB:  PubMed          Journal:  Langmuir        ISSN: 0743-7463            Impact factor:   3.882


  6 in total

1.  Three-Dimensional Cell Entrapment as a Function of the Weight Percent of Peptide-Amphiphile Hydrogels.

Authors:  Carolyn M Scott; Colleen L Forster; Efrosini Kokkoli
Journal:  Langmuir       Date:  2015-05-26       Impact factor: 3.882

2.  Targeting LC3 and Beclin-1 autophagy genes suppresses proliferation, survival, migration and invasion by inhibition of Cyclin-D1 and uPAR/Integrin β1/ Src signaling in triple negative breast cancer cells.

Authors:  Zuhal Hamurcu; Nesrin Delibaşı; Seda Geçene; Elif Funda Şener; Hamiyet Dönmez-Altuntaş; Yusuf Özkul; Halit Canatan; Bulent Ozpolat
Journal:  J Cancer Res Clin Oncol       Date:  2017-12-29       Impact factor: 4.553

Review 3.  Self-Assembled Peptide Nanostructures for ECM Biomimicry.

Authors:  Davide Marin; Silvia Marchesan
Journal:  Nanomaterials (Basel)       Date:  2022-06-22       Impact factor: 5.719

4.  Maintenance of ischemic β cell viability through delivery of lipids and ATP by targeted liposomes.

Authors:  Nicole Atchison; Garrett Swindlehurst; Klearchos K Papas; Michael Tsapatsis; Efrosini Kokkoli
Journal:  Biomater Sci       Date:  2014-04-01       Impact factor: 6.843

5.  Induction of albumin expression in HepG2 cells using immobilized simplified recombinant fibronectin protein.

Authors:  Yuuki Nishida; Akiyoshi Taniguchi
Journal:  In Vitro Cell Dev Biol Anim       Date:  2013-05-07       Impact factor: 2.416

6.  The Osteogenic Differentiation Effect of the FN Type 10-Peptide Amphiphile on PCL Fiber.

Authors:  Ye-Rang Yun; Hae-Won Kim; Jun-Hyeog Jang
Journal:  Int J Mol Sci       Date:  2018-01-04       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.